If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
NUFYMCO BLA has been approved by the USFDA
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The fresh capital will propel Cordance into its first-in-human clinical trial
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Subscribe To Our Newsletter & Stay Updated
